首页 > 最新文献

Frontiers in Medicine最新文献

英文 中文
Efficacy of Kegan Liyan oral liquid vs. Lianhuaqingwen capsules for patients with mild COVID-19: a double-blinded, randomized, controlled, non-inferiority trial.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1531370
Yuewei Li, Yihe Chi, Mengting Zhu, Feiting Fan, Zhongyang Deng, Jingmin Xiao, Shaohan Jin, Luoqi Lin, Xiaochun Chen, Ruhong Xu, Long Fan, Xuhua Yu, Ziyao Liang, Jingyu Quan, Shangzhao Li, Xinying Peng, Yuanbin Chen, Lin Lin, Lei Wu

Background: Traditional Chinese medicine has been used for Coronavirus disease 2019 (COVID-19) as a therapeutic option. Lianhuaqingwen capsules (LHQW) are well-recognized for their efficacy, while Kegan Liyan oral liquid (KGLY), widely used for influenza treatment, has emerged as a promising candidate for COVID-19 therapy. This trial aims to assess whether KGLY is non-inferior to LHQW in treating mild COVID-19.

Methods: A total of 127 participants (63 in KGLY group and 64 in LHQW group) were randomly allocated to receive either KGLY therapy or LHQW therapy in a 1:1 ratio. The treatment was given for 7 days, and the follow-up period was 3 days.

Outcome measures: The primary outcome was symptom remission at day 10. Secondary outcomes included symptom recovery, time to symptom remission, recovery rates and time to recovery of selected symptoms, change in visual analog scale score for selected symptoms, area under the curve of the visual analog scale score for sore throat, negative conversion of the SARS-CoV-2 infection, having a positive test result after negative conversion, and incidence of pneumonia.

Results: Full analysis set analysis showed that the symptom remission rate at day 10 was 60.7% with KGLY and 58.3% in LHQW (difference + 2.3 p.p., lower limit of 95% confidence interval - 14.8 p.p.), indicating non-inferiority. There were no significant differences between the groups for any secondary outcome. The occurrence of adverse events did not differ between the groups and no severe adverse events were documented in either group.

Conclusion: Based on the study results, this trial proved that KGLY was non-inferior to LHQW for mild COVID-19, providing a promising option for COVID-19 treatment.

Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=166372, Identifier, [ChiCTR2200059105].

{"title":"Efficacy of Kegan Liyan oral liquid vs. Lianhuaqingwen capsules for patients with mild COVID-19: a double-blinded, randomized, controlled, non-inferiority trial.","authors":"Yuewei Li, Yihe Chi, Mengting Zhu, Feiting Fan, Zhongyang Deng, Jingmin Xiao, Shaohan Jin, Luoqi Lin, Xiaochun Chen, Ruhong Xu, Long Fan, Xuhua Yu, Ziyao Liang, Jingyu Quan, Shangzhao Li, Xinying Peng, Yuanbin Chen, Lin Lin, Lei Wu","doi":"10.3389/fmed.2025.1531370","DOIUrl":"10.3389/fmed.2025.1531370","url":null,"abstract":"<p><strong>Background: </strong>Traditional Chinese medicine has been used for Coronavirus disease 2019 (COVID-19) as a therapeutic option. Lianhuaqingwen capsules (LHQW) are well-recognized for their efficacy, while Kegan Liyan oral liquid (KGLY), widely used for influenza treatment, has emerged as a promising candidate for COVID-19 therapy. This trial aims to assess whether KGLY is non-inferior to LHQW in treating mild COVID-19.</p><p><strong>Methods: </strong>A total of 127 participants (63 in KGLY group and 64 in LHQW group) were randomly allocated to receive either KGLY therapy or LHQW therapy in a 1:1 ratio. The treatment was given for 7 days, and the follow-up period was 3 days.</p><p><strong>Outcome measures: </strong>The primary outcome was symptom remission at day 10. Secondary outcomes included symptom recovery, time to symptom remission, recovery rates and time to recovery of selected symptoms, change in visual analog scale score for selected symptoms, area under the curve of the visual analog scale score for sore throat, negative conversion of the SARS-CoV-2 infection, having a positive test result after negative conversion, and incidence of pneumonia.</p><p><strong>Results: </strong>Full analysis set analysis showed that the symptom remission rate at day 10 was 60.7% with KGLY and 58.3% in LHQW (difference + 2.3 p.p., lower limit of 95% confidence interval - 14.8 p.p.), indicating non-inferiority. There were no significant differences between the groups for any secondary outcome. The occurrence of adverse events did not differ between the groups and no severe adverse events were documented in either group.</p><p><strong>Conclusion: </strong>Based on the study results, this trial proved that KGLY was non-inferior to LHQW for mild COVID-19, providing a promising option for COVID-19 treatment.</p><p><strong>Clinical trial registration: </strong>https://www.chictr.org.cn/showproj.html?proj=166372, Identifier, [ChiCTR2200059105].</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1531370"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of therapeutic exercise for primary dysmenorrhea: a systematic review and meta-analysis.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1540557
Yi Xiang, Qinhai Li, Zengao Lu, Zemin Yu, Guanglin Ma, Siqi Liu, Yingkui Li

Objective: A growing number of research papers have looked at the influence of exercise on pain severity in people with primary dysmenorrhea, but the findings have been inconsistent. The purpose of this research was to thoroughly evaluate the impact of exercise on pain severity in individuals with primary dysmenorrhea and to find the best exercise regimen for these patients.

Methods: All randomized controlled trials (RCTs) of exercise for patients with primary dysmenorrhea were searched in the Embase, PubMed, Cochrane, Web of Science, EBSCO, and CINAHL databases. The search time limit was set from the establishment of each database to 28 January 2025. Control groups included those receiving usual care, only providing health education, or no intervention at all. The outcome measure was pain intensity. The effect size was aggregated using the mean difference (MD) and 95% confidence interval (CI). The methodological quality of the included studies was evaluated using the Cochrane risk-of-bias tool. Stata 15 software was used for meta-analysis, sensitivity analysis, and assessment of potential publication bias. R 4.4.1 software was used for network meta-analysis, area under curve ranking (SUCRA), league plot, and meta-regression.

Results: The analysis included a total of 29 studies that satisfied the criteria. Exercise decreased the visual analog scale (VAS, WMD = -2.62, 95% CI [-3.29, -1.95], p < 0.001) score in individuals with primary dysmenorrhea. Strength training (WMD = -1.76, 95% CI [-2.03, -1.48], p < 0.001), exercise duration of ≥8 weeks (WMD = -1.77, 95% CI [-1.87, -1.66], p < 0.001), frequency of >3 times per week (WMD = -1.60, 95% CI [-1.75, -1.45], p < 0.001), session length of >30 min (WMD = -2.20, 95% CI [-2.38, -2.02], p < 0.001), and a total of ≥90 min per week (WMD = -2.04, 95% CI [-2.19, -1.89], p < 0.001) showed superior efficacy in enhancing VAS (subgroup analyses).

Conclusion: Engaging in physical activity may reduce the intensity of discomfort encountered by individuals afflicted with primary dysmenorrhea, with strength training potentially emerging as the most efficacious alternative. The meta-analysis presents evidence that supports clinicians' advice to patients with primary dysmenorrhea, recommending that they exercise for a minimum of 8 weeks, with sessions occurring more than three times weekly and lasting longer than 30 min each. The goal is to achieve a minimum weekly total of 90 min by increasing the frequency of workouts.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024581879, CRD42024581879.

{"title":"Efficacy and safety of therapeutic exercise for primary dysmenorrhea: a systematic review and meta-analysis.","authors":"Yi Xiang, Qinhai Li, Zengao Lu, Zemin Yu, Guanglin Ma, Siqi Liu, Yingkui Li","doi":"10.3389/fmed.2025.1540557","DOIUrl":"10.3389/fmed.2025.1540557","url":null,"abstract":"<p><strong>Objective: </strong>A growing number of research papers have looked at the influence of exercise on pain severity in people with primary dysmenorrhea, but the findings have been inconsistent. The purpose of this research was to thoroughly evaluate the impact of exercise on pain severity in individuals with primary dysmenorrhea and to find the best exercise regimen for these patients.</p><p><strong>Methods: </strong>All randomized controlled trials (RCTs) of exercise for patients with primary dysmenorrhea were searched in the Embase, PubMed, Cochrane, Web of Science, EBSCO, and CINAHL databases. The search time limit was set from the establishment of each database to 28 January 2025. Control groups included those receiving usual care, only providing health education, or no intervention at all. The outcome measure was pain intensity. The effect size was aggregated using the mean difference (MD) and 95% confidence interval (CI). The methodological quality of the included studies was evaluated using the Cochrane risk-of-bias tool. Stata 15 software was used for meta-analysis, sensitivity analysis, and assessment of potential publication bias. R 4.4.1 software was used for network meta-analysis, area under curve ranking (SUCRA), league plot, and meta-regression.</p><p><strong>Results: </strong>The analysis included a total of 29 studies that satisfied the criteria. Exercise decreased the visual analog scale (VAS, WMD = -2.62, 95% CI [-3.29, -1.95], <i>p</i> < 0.001) score in individuals with primary dysmenorrhea. Strength training (WMD = -1.76, 95% CI [-2.03, -1.48], <i>p</i> < 0.001), exercise duration of ≥8 weeks (WMD = -1.77, 95% CI [-1.87, -1.66], <i>p</i> < 0.001), frequency of >3 times per week (WMD = -1.60, 95% CI [-1.75, -1.45], <i>p</i> < 0.001), session length of >30 min (WMD = -2.20, 95% CI [-2.38, -2.02], <i>p</i> < 0.001), and a total of ≥90 min per week (WMD = -2.04, 95% CI [-2.19, -1.89], <i>p</i> < 0.001) showed superior efficacy in enhancing VAS (subgroup analyses).</p><p><strong>Conclusion: </strong>Engaging in physical activity may reduce the intensity of discomfort encountered by individuals afflicted with primary dysmenorrhea, with strength training potentially emerging as the most efficacious alternative. The meta-analysis presents evidence that supports clinicians' advice to patients with primary dysmenorrhea, recommending that they exercise for a minimum of 8 weeks, with sessions occurring more than three times weekly and lasting longer than 30 min each. The goal is to achieve a minimum weekly total of 90 min by increasing the frequency of workouts.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024581879, CRD42024581879.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1540557"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe Chlamydia psittaci pneumonia complicated by deep vein thrombosis: a case report.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1527556
Anbing Zhang, Ting Huang, Xiaoli Lao, Jun Ma, Xiuqiong Xia, Jianping Liang

Deep vein thrombosis (DVT) of the legs is a rare but clinically important complication of Chlamydia psittaci pneumonia. We report a case of a 51-year-old man who was admitted to the hospital with fever, cough, and dyspnea. Next-generation sequencing confirmed the diagnosis of Chlamydia psittaci pneumonia. His D-dimer level was elevated on admission, and ultrasound confirmed DVT in the legs. The patient was treated with intravenous doxycycline for the infection and rivaroxaban as an anticoagulant. His condition gradually improved and he was discharged after making a full recovery. In this paper, we explore the potential association between Chlamydia psittaci infection and venous thrombosis, as well as clinical management strategies.

{"title":"Severe <i>Chlamydia psittaci</i> pneumonia complicated by deep vein thrombosis: a case report.","authors":"Anbing Zhang, Ting Huang, Xiaoli Lao, Jun Ma, Xiuqiong Xia, Jianping Liang","doi":"10.3389/fmed.2025.1527556","DOIUrl":"10.3389/fmed.2025.1527556","url":null,"abstract":"<p><p>Deep vein thrombosis (DVT) of the legs is a rare but clinically important complication of <i>Chlamydia psittaci</i> pneumonia. We report a case of a 51-year-old man who was admitted to the hospital with fever, cough, and dyspnea. Next-generation sequencing confirmed the diagnosis of <i>Chlamydia psittaci</i> pneumonia. His D-dimer level was elevated on admission, and ultrasound confirmed DVT in the legs. The patient was treated with intravenous doxycycline for the infection and rivaroxaban as an anticoagulant. His condition gradually improved and he was discharged after making a full recovery. In this paper, we explore the potential association between <i>Chlamydia psittaci</i> infection and venous thrombosis, as well as clinical management strategies.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1527556"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Data altruism and the "consent" question: a study into the "consent" models used under the GDPR and how the data altruism mechanism can act as a potential solution for the research community in the reuse of health data.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-25 eCollection Date: 2024-01-01 DOI: 10.3389/fmed.2024.1489925
Maria Christofidou, Theodoros N Arvanitis, Dipak Kalra, Nathan Lea, Mahsa Shabani, Pascal Coorevits
<p><strong>Introduction: </strong>The General Data Protection Regulation ("GDPR") legal basis for obtaining consent for the processing of personal data for research purposes, where those purposes cannot be fully specified in advance, is provided for in Articles 6, 7 and Recital 33. However, GDPR's requirements for obtaining consent, as to the secondary use and sharing of data in research, have been argued to have generated confusion, whilst the conflicts between the Regulation itself, its practical application and research ethics are well-documented (1). The requirements for "informed consent", as defined within the GDPR, have not been well defined in the context of genome research or clinical trials (2), which has in turn led to the implementation and interpretation of the lawful basis to span into different idiosyncratic models. This naturally has fed into the uncertainty of how the legal basis can be applied in practice and calls for an investigation into the requirements for consent to be "informed" in the context of health research. This work aims to provide a scoping review and analysis of relevant publications with ultimate purpose to examine whether the concept of 'data altruism', as stipulated within Article 2 (10) of the Data Governance Act ("DGA"), addresses the gaps left behind by the application of the legal basis of 'consent', under the GDPR (Art. 6 (1) and 7), in so far as the secondary uses of data for research are concerned. In this light the article, by exploring available solutions found in relevant literature and used in practice in national and European projects, examines how 'data altruism' can add any value and work as a cohesive solution that the research community can use.</p><p><strong>Objectives: </strong>The article, through its research, intends to answer the following questions:What gaps has the GDPR left when it comes to the interpretation and practical application of "consent" towards the secondary use of health data;Can the DGA, through the mechanism of 'data altruism', address these issues and provide a solution;What solutions have been used so far in practice to address this issue.</p><p><strong>Methodology: </strong>To address the above-mentioned questions, the Arskey and O'Malley scoping review methodology and best practice, as outlined in the Joanna Briggs scoping review guidelines, have been applied. The research questions have been identified through an extensive literature review and consultation with subject matter experts. The search was conducted using six search engines and utilising a tailored search strategy, with the application of both MESH and non-MESH based search terms. From the identified relevant publications, 148 abstracts were kept to be read and 60 of those publications were kept as relevant. A PRISMA chart showcases the process in which the publications were reviewed and the process which led to the final papers kept as relevant. The title-abstract and full text screening and charting the
{"title":"Data altruism and the \"consent\" question: a study into the \"consent\" models used under the GDPR and how the data altruism mechanism can act as a potential solution for the research community in the reuse of health data.","authors":"Maria Christofidou, Theodoros N Arvanitis, Dipak Kalra, Nathan Lea, Mahsa Shabani, Pascal Coorevits","doi":"10.3389/fmed.2024.1489925","DOIUrl":"10.3389/fmed.2024.1489925","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;The General Data Protection Regulation (\"GDPR\") legal basis for obtaining consent for the processing of personal data for research purposes, where those purposes cannot be fully specified in advance, is provided for in Articles 6, 7 and Recital 33. However, GDPR's requirements for obtaining consent, as to the secondary use and sharing of data in research, have been argued to have generated confusion, whilst the conflicts between the Regulation itself, its practical application and research ethics are well-documented (1). The requirements for \"informed consent\", as defined within the GDPR, have not been well defined in the context of genome research or clinical trials (2), which has in turn led to the implementation and interpretation of the lawful basis to span into different idiosyncratic models. This naturally has fed into the uncertainty of how the legal basis can be applied in practice and calls for an investigation into the requirements for consent to be \"informed\" in the context of health research. This work aims to provide a scoping review and analysis of relevant publications with ultimate purpose to examine whether the concept of 'data altruism', as stipulated within Article 2 (10) of the Data Governance Act (\"DGA\"), addresses the gaps left behind by the application of the legal basis of 'consent', under the GDPR (Art. 6 (1) and 7), in so far as the secondary uses of data for research are concerned. In this light the article, by exploring available solutions found in relevant literature and used in practice in national and European projects, examines how 'data altruism' can add any value and work as a cohesive solution that the research community can use.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;The article, through its research, intends to answer the following questions:What gaps has the GDPR left when it comes to the interpretation and practical application of \"consent\" towards the secondary use of health data;Can the DGA, through the mechanism of 'data altruism', address these issues and provide a solution;What solutions have been used so far in practice to address this issue.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methodology: &lt;/strong&gt;To address the above-mentioned questions, the Arskey and O'Malley scoping review methodology and best practice, as outlined in the Joanna Briggs scoping review guidelines, have been applied. The research questions have been identified through an extensive literature review and consultation with subject matter experts. The search was conducted using six search engines and utilising a tailored search strategy, with the application of both MESH and non-MESH based search terms. From the identified relevant publications, 148 abstracts were kept to be read and 60 of those publications were kept as relevant. A PRISMA chart showcases the process in which the publications were reviewed and the process which led to the final papers kept as relevant. The title-abstract and full text screening and charting the ","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"11 ","pages":"1489925"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose determination of VV116 in COVID-19 patients with severe liver dysfunction: a case report.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1541235
Jing Yang, Wenwen Jiang, Jianqing Deng, Min Liu, Ya Xue, Jizhang Bao, Tingting Jia, Qi Hu, Lichao Zhang

VV116 is an oral antiviral drug against SARS-CoV-2, known for its favorable efficacy and safety profile. But its application in patients with severe liver dysfunction has not been evaluated. Here, we report a case in which a patient with aplastic anemia and liver impairment (recovery phase of acute liver failure) was infected with SARS-CoV-2. Based on clinical trials and pharmacokinetic analysis about VV116, we initiated a reduced dose of 300 mg every 12 h on day 1, 200 mg every 12 h on days 2-5 for antiviral therapy. Finally, the patient's viral load rapidly dropped to an undetected level, and no drug-related adverse effects were observed.

{"title":"Dose determination of VV116 in COVID-19 patients with severe liver dysfunction: a case report.","authors":"Jing Yang, Wenwen Jiang, Jianqing Deng, Min Liu, Ya Xue, Jizhang Bao, Tingting Jia, Qi Hu, Lichao Zhang","doi":"10.3389/fmed.2025.1541235","DOIUrl":"10.3389/fmed.2025.1541235","url":null,"abstract":"<p><p>VV116 is an oral antiviral drug against SARS-CoV-2, known for its favorable efficacy and safety profile. But its application in patients with severe liver dysfunction has not been evaluated. Here, we report a case in which a patient with aplastic anemia and liver impairment (recovery phase of acute liver failure) was infected with SARS-CoV-2. Based on clinical trials and pharmacokinetic analysis about VV116, we initiated a reduced dose of 300 mg every 12 h on day 1, 200 mg every 12 h on days 2-5 for antiviral therapy. Finally, the patient's viral load rapidly dropped to an undetected level, and no drug-related adverse effects were observed.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1541235"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of glucocorticoids in preventing esophageal stricture and predictors of stricture after esophageal ESD: 5 years of experience in a single medical center.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1428508
Qingxia Wang, Yuan Ding, Qiliu Qian, Yinnan Zhu, Ruihua Shi

Background: Esophageal stricture is one of the major complications after endoscopic submucosal dissection (ESD) of the esophagus. However, even with steroid prophylaxis, stenosis still occurs in up to 45% of patients. Accordingly, the aim of this study was to evaluate the efficacy and safety of steroid therapy in preventing esophageal strictures after ESD, as well as to assess the predictors of esophageal strictures after the application of steroids.

Methods: Between February 2018 and March 2023, 207 patients who underwent esophageal ESD at Southeast University Affiliated Zhongda Hospital were retrospectively enrolled. We evaluated stenosis rate, number of endoscopic dilations after ESD, the interval between the first endoscopic dilatation after ESD and explored risk factors for strictures after steroid prophylaxis.

Results: In the control group, the oral steroids group, and the combined group, the stenosis rates were 83/87 (95.4%), 44/53 (83.0%), and 56/67 (83.6%), respectively; the number of endoscopic dilations were 3.43 (±2.22), 2.34 (±2.17), and 1.52 (±1.25), respectively; the time intervals between first endoscopic dilation and ESD procedure were 38.36 (±6.87), 68.18 (±9.49), and 96.82 (±8.41) days, respectively; all these indicators were significantly better in the oral and combined groups than in the control group (p < 0.05). Multivariate analysis identified lesion circumference ≥ 5/6th and submucosal injection of solution were two independent factors on esophageal stricture formation (p < 0.05).

Conclusion: Steroid prophylaxis is effective and safe in preventing esophageal stenosis. Moreover, lesion circumference and submucosal injection of sodium hyaluronate were two independent factors on esophageal stricture formation even with steroids administration.

{"title":"Effectiveness of glucocorticoids in preventing esophageal stricture and predictors of stricture after esophageal ESD: 5 years of experience in a single medical center.","authors":"Qingxia Wang, Yuan Ding, Qiliu Qian, Yinnan Zhu, Ruihua Shi","doi":"10.3389/fmed.2025.1428508","DOIUrl":"10.3389/fmed.2025.1428508","url":null,"abstract":"<p><strong>Background: </strong>Esophageal stricture is one of the major complications after endoscopic submucosal dissection (ESD) of the esophagus. However, even with steroid prophylaxis, stenosis still occurs in up to 45% of patients. Accordingly, the aim of this study was to evaluate the efficacy and safety of steroid therapy in preventing esophageal strictures after ESD, as well as to assess the predictors of esophageal strictures after the application of steroids.</p><p><strong>Methods: </strong>Between February 2018 and March 2023, 207 patients who underwent esophageal ESD at Southeast University Affiliated Zhongda Hospital were retrospectively enrolled. We evaluated stenosis rate, number of endoscopic dilations after ESD, the interval between the first endoscopic dilatation after ESD and explored risk factors for strictures after steroid prophylaxis.</p><p><strong>Results: </strong>In the control group, the oral steroids group, and the combined group, the stenosis rates were 83/87 (95.4%), 44/53 (83.0%), and 56/67 (83.6%), respectively; the number of endoscopic dilations were 3.43 (±2.22), 2.34 (±2.17), and 1.52 (±1.25), respectively; the time intervals between first endoscopic dilation and ESD procedure were 38.36 (±6.87), 68.18 (±9.49), and 96.82 (±8.41) days, respectively; all these indicators were significantly better in the oral and combined groups than in the control group (<i>p</i> < 0.05). Multivariate analysis identified lesion circumference ≥ 5/6th and submucosal injection of solution were two independent factors on esophageal stricture formation (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Steroid prophylaxis is effective and safe in preventing esophageal stenosis. Moreover, lesion circumference and submucosal injection of sodium hyaluronate were two independent factors on esophageal stricture formation even with steroids administration.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1428508"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perceived value and barriers of nursing specialty certifications among clinical nurses in Saudi Arabia: a cross-sectional study.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1528856
Alawiah T AlSadah, Ahmad E Aboshaiqah, Naif H Alanazi

Introduction: Specialty nursing certifications reflect nurse's knowledge and competence in certain areas. Obtaining certification allows them to advance their careers and enhance patient care standards as their role and scope of responsibility expands. This study aimed to understand how nurses view specialty certification and related challenges in three university hospitals in Riyadh, Saudi Arabia.

Methods: A cross-sectional, correlational design was used. A survey questionnaire (Perceived Value of Certification-12 Tool) was sent through email, and it had one question for each barrier.

Results: The majority of participants valued certification to verify specialist knowledge (93.9%), enhance achievement (82.8%), and increase competence (79.1%). Certification was associated extrinsically with hiring preference (54.7%), recognition from colleagues (52.3%), and professional autonomy (51.7%). The primary barriers were lack of institutional reward (72.7%) and examination cost (64.8%), with not passing earlier being the least mentioned barrier (2%). The biggest obstacles faced by clinical nurses in obtaining certification include limited institutional rewards because their organization did offer incentives, such as promotions or salary bumps. Age and hospital significantly predicted clinical nurses' intrinsic value of certification, while age, gender, nationality, and hospital significantly predicted their extrinsic value. Age and gender significantly influenced their overall perceived value of certification.

Discussion: Overall, nurses in Riyadh recognize the value of certification. However, focused interventions must be implemented to overcome identified challenges and amplify the professional benefits of certification. Recommended measures include implementing tailored support initiatives and financial aid programs to address these barriers. A collaborative approach should be developed to provide support and actively promote the pursuit of nursing certification. Future studies should adopt longitudinal and qualitative designs to evaluate the impact of focused strategies.

{"title":"Perceived value and barriers of nursing specialty certifications among clinical nurses in Saudi Arabia: a cross-sectional study.","authors":"Alawiah T AlSadah, Ahmad E Aboshaiqah, Naif H Alanazi","doi":"10.3389/fmed.2025.1528856","DOIUrl":"10.3389/fmed.2025.1528856","url":null,"abstract":"<p><strong>Introduction: </strong>Specialty nursing certifications reflect nurse's knowledge and competence in certain areas. Obtaining certification allows them to advance their careers and enhance patient care standards as their role and scope of responsibility expands. This study aimed to understand how nurses view specialty certification and related challenges in three university hospitals in Riyadh, Saudi Arabia.</p><p><strong>Methods: </strong>A cross-sectional, correlational design was used. A survey questionnaire (Perceived Value of Certification-12 Tool) was sent through email, and it had one question for each barrier.</p><p><strong>Results: </strong>The majority of participants valued certification to verify specialist knowledge (93.9%), enhance achievement (82.8%), and increase competence (79.1%). Certification was associated extrinsically with hiring preference (54.7%), recognition from colleagues (52.3%), and professional autonomy (51.7%). The primary barriers were lack of institutional reward (72.7%) and examination cost (64.8%), with not passing earlier being the least mentioned barrier (2%). The biggest obstacles faced by clinical nurses in obtaining certification include limited institutional rewards because their organization did offer incentives, such as promotions or salary bumps. Age and hospital significantly predicted clinical nurses' intrinsic value of certification, while age, gender, nationality, and hospital significantly predicted their extrinsic value. Age and gender significantly influenced their overall perceived value of certification.</p><p><strong>Discussion: </strong>Overall, nurses in Riyadh recognize the value of certification. However, focused interventions must be implemented to overcome identified challenges and amplify the professional benefits of certification. Recommended measures include implementing tailored support initiatives and financial aid programs to address these barriers. A collaborative approach should be developed to provide support and actively promote the pursuit of nursing certification. Future studies should adopt longitudinal and qualitative designs to evaluate the impact of focused strategies.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1528856"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abnormality-aware multimodal learning for WSI classification.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1546452
Thao M Dang, Qifeng Zhou, Yuzhi Guo, Hehuan Ma, Saiyang Na, Thao Bich Dang, Jean Gao, Junzhou Huang

Whole slide images (WSIs) play a vital role in cancer diagnosis and prognosis. However, their gigapixel resolution, lack of pixel-level annotations, and reliance on unimodal visual data present challenges for accurate and efficient computational analysis. Existing methods typically divide WSIs into thousands of patches, which increases computational demands and makes it challenging to effectively focus on diagnostically relevant regions. Furthermore, these methods frequently rely on feature extractors pretrained on natural images, which are not optimized for pathology tasks, and overlook multimodal data sources such as cellular and textual information that can provide critical insights. To address these limitations, we propose the Abnormality-Aware MultiModal (AAMM) learning framework, which integrates abnormality detection and multimodal feature learning for WSI classification. AAMM incorporates a Gaussian Mixture Variational Autoencoder (GMVAE) to identify and select the most informative patches, reducing computational complexity while retaining critical diagnostic information. It further integrates multimodal features from pathology-specific foundation models, combining patch-level, cell-level, and text-level representations through cross-attention mechanisms. This approach enhances the ability to comprehensively analyze WSIs for cancer diagnosis and subtyping. Extensive experiments on normal-tumor classification and cancer subtyping demonstrate that AAMM achieves superior performance compared to state-of-the-art methods. By combining abnormal detection with multimodal feature integration, our framework offers an efficient and scalable solution for advancing computational pathology.

{"title":"Abnormality-aware multimodal learning for WSI classification.","authors":"Thao M Dang, Qifeng Zhou, Yuzhi Guo, Hehuan Ma, Saiyang Na, Thao Bich Dang, Jean Gao, Junzhou Huang","doi":"10.3389/fmed.2025.1546452","DOIUrl":"10.3389/fmed.2025.1546452","url":null,"abstract":"<p><p>Whole slide images (WSIs) play a vital role in cancer diagnosis and prognosis. However, their gigapixel resolution, lack of pixel-level annotations, and reliance on unimodal visual data present challenges for accurate and efficient computational analysis. Existing methods typically divide WSIs into thousands of patches, which increases computational demands and makes it challenging to effectively focus on diagnostically relevant regions. Furthermore, these methods frequently rely on feature extractors pretrained on natural images, which are not optimized for pathology tasks, and overlook multimodal data sources such as cellular and textual information that can provide critical insights. To address these limitations, we propose the <b>A</b>bnormality-<b>A</b>ware <b>M</b>ulti<b>M</b>odal (AAMM) learning framework, which integrates abnormality detection and multimodal feature learning for WSI classification. AAMM incorporates a Gaussian Mixture Variational Autoencoder (GMVAE) to identify and select the most informative patches, reducing computational complexity while retaining critical diagnostic information. It further integrates multimodal features from pathology-specific foundation models, combining patch-level, cell-level, and text-level representations through cross-attention mechanisms. This approach enhances the ability to comprehensively analyze WSIs for cancer diagnosis and subtyping. Extensive experiments on normal-tumor classification and cancer subtyping demonstrate that AAMM achieves superior performance compared to state-of-the-art methods. By combining abnormal detection with multimodal feature integration, our framework offers an efficient and scalable solution for advancing computational pathology.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1546452"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proposed research classification criteria for Lyme disease in infection associated chronic illness studies.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1519163
Brian A Fallon, Mara Kuvaldina, Nevena Zubcevik, Roberta DeBiasi, Sarah B Mulkey, Charles Chiu, Felicia Chow, Kristopher Paolino, Randy Lai, David Putrino, Amy Proal, Martina Pavlicova, John Aucott

Background: Research on patients with persistent symptoms despite prior treatment for Lyme disease can be challenging to interpret given the diversity of criteria selected to characterize Lyme disease and to define the syndrome of those with persistent symptoms. Because most research studies only include patients with well-documented prior Lyme disease, the generalizability of the study results is limited, excluding the larger group of patients often seen in community practice who do not meet these stringent enrollment criteria. Researchers at the Lyme and other Tick-borne Diseases Clinical Trials Network (LTD-CTN) recognized early on that a research classification system was needed to facilitate the design of studies that are more inclusive. This paper presents a proposed research classification system.

Methods: Criteria used in published clinical research on previously treated Lyme disease were reviewed. Clinical expertise was provided by principal investigators in the LTD-CTN. Further input was obtained from a diverse panel of stakeholders in the field, including clinicians, academic researchers, and patient advocates. This classification system was developed based on feedback collected from all these sources.

Results: The new research classification system proposes criteria for Lyme disease at different levels of diagnostic certainty: well-defined, probable, possible, and uncertain. Criteria for ascertainment for each classification level and additional factors to be considered in patient selection for research are described.

Conclusion: The proposed research classification system should improve the quality and generalizability of clinical research by providing clear case definitions for enrollment of a more diverse group of patients with sequelae from Lyme disease.

{"title":"Proposed research classification criteria for Lyme disease in infection associated chronic illness studies.","authors":"Brian A Fallon, Mara Kuvaldina, Nevena Zubcevik, Roberta DeBiasi, Sarah B Mulkey, Charles Chiu, Felicia Chow, Kristopher Paolino, Randy Lai, David Putrino, Amy Proal, Martina Pavlicova, John Aucott","doi":"10.3389/fmed.2025.1519163","DOIUrl":"10.3389/fmed.2025.1519163","url":null,"abstract":"<p><strong>Background: </strong>Research on patients with persistent symptoms despite prior treatment for Lyme disease can be challenging to interpret given the diversity of criteria selected to characterize Lyme disease and to define the syndrome of those with persistent symptoms. Because most research studies only include patients with well-documented prior Lyme disease, the generalizability of the study results is limited, excluding the larger group of patients often seen in community practice who do not meet these stringent enrollment criteria. Researchers at the Lyme and other Tick-borne Diseases Clinical Trials Network (LTD-CTN) recognized early on that a research classification system was needed to facilitate the design of studies that are more inclusive. This paper presents a proposed research classification system.</p><p><strong>Methods: </strong>Criteria used in published clinical research on previously treated Lyme disease were reviewed. Clinical expertise was provided by principal investigators in the LTD-CTN. Further input was obtained from a diverse panel of stakeholders in the field, including clinicians, academic researchers, and patient advocates. This classification system was developed based on feedback collected from all these sources.</p><p><strong>Results: </strong>The new research classification system proposes criteria for Lyme disease at different levels of diagnostic certainty: well-defined, probable, possible, and uncertain. Criteria for ascertainment for each classification level and additional factors to be considered in patient selection for research are described.</p><p><strong>Conclusion: </strong>The proposed research classification system should improve the quality and generalizability of clinical research by providing clear case definitions for enrollment of a more diverse group of patients with sequelae from Lyme disease.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1519163"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Doctor for a day: the impact of a health professions enrichment program on self-efficacy.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1511405
Celeste Coler, Kareena Patel, A J Balatico, Kumhee Ro, Joshua Villarreal, Nora Coronado, Estell Williams

Introduction: Health profession enrichment programs for underrepresented minority students are crucial to supporting students' interest in healthcare careers and improving preparedness for important academic and professional milestones. Doctor for a Day, an enrichment program at the University of Washington School of Medicine, hosts monthly events where underrepresented kindergarten-12th grade students are exposed to careers in medicine by healthcare professionals from diverse backgrounds.

Methods: This study investigates to what extent participation in Doctor for a Day programming improves self-efficacy using a survey study of 958 students who attended at least one Doctor for a Day event between 2017 and 2023.

Results: Using an evaluation tool composed of six questions, our results demonstrate that participation in Doctor for a Day programming increases self-efficacy and interest in medicine as a career. Analysis of these results found significant differences in responses based on grade level, with students in high school demonstrating the largest improvement in self-efficacy.

Discussion: These findings underscore the value of such enrichment programs and offer insights for the development of similar initiatives.

{"title":"Doctor for a day: the impact of a health professions enrichment program on self-efficacy.","authors":"Celeste Coler, Kareena Patel, A J Balatico, Kumhee Ro, Joshua Villarreal, Nora Coronado, Estell Williams","doi":"10.3389/fmed.2025.1511405","DOIUrl":"10.3389/fmed.2025.1511405","url":null,"abstract":"<p><strong>Introduction: </strong>Health profession enrichment programs for underrepresented minority students are crucial to supporting students' interest in healthcare careers and improving preparedness for important academic and professional milestones. Doctor for a Day, an enrichment program at the University of Washington School of Medicine, hosts monthly events where underrepresented kindergarten-12th grade students are exposed to careers in medicine by healthcare professionals from diverse backgrounds.</p><p><strong>Methods: </strong>This study investigates to what extent participation in Doctor for a Day programming improves self-efficacy using a survey study of 958 students who attended at least one Doctor for a Day event between 2017 and 2023.</p><p><strong>Results: </strong>Using an evaluation tool composed of six questions, our results demonstrate that participation in Doctor for a Day programming increases self-efficacy and interest in medicine as a career. Analysis of these results found significant differences in responses based on grade level, with students in high school demonstrating the largest improvement in self-efficacy.</p><p><strong>Discussion: </strong>These findings underscore the value of such enrichment programs and offer insights for the development of similar initiatives.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1511405"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1